ライフサイエンスコーパス: cisplatin-DNA adduct

1 e) analogue is located to the 5' side of the cisplatin-DNA adduct.

2 2-7 s-1 ), with larger effects closer to the cisplatin-DNA adduct.

3 so the propeller twisted base pairs near the cisplatin-DNA adduct.

4 same substrate containing a single 1,2d(GpG) cisplatin-DNA adduct.

5 h repair proteins function as a detector for cisplatin DNA adducts.

6 he presence of DNA-distorting damage such as cisplatin-DNA adducts.

7 ct of the 5'-group, favoring left canting in cisplatin-DNA adducts.

8 ing of rhRPA to DNA containing site-specific cisplatin-DNA adducts.

9 y contributes to the accumulative pattern of cisplatin-DNA adducts.

10 and other proteins that bind specifically to cisplatin-DNA adducts.

11 y for many DNA-distorting lesions, including cisplatin-DNA adducts.

12 ts Pol eta in a manner distinct from that of cisplatin-DNA adducts.

13 n testes, uniquely blocks excision repair of cisplatin-DNA adducts, 1,2-intrastrand cross-links, to p

14 Proteins that discriminate between cisplatin-DNA adducts and oxaliplatin-DNA adducts are th

15 ssion of ACTL6A leads to increased repair of cisplatin-DNA adducts and resistance to cisplatin treatm

16 teins can block excision repair of the major cisplatin-DNA adducts and suggest that such an activity

17 are discussed with respect to the repair of cisplatin-DNA adducts and the role of DNA-PK in coordina

18 or a 1,3d(GXG), intermediate for a 1,2d(GpG) cisplatin-DNA adduct, and least for an undamaged duplex

19 mplications for the biological processing of cisplatin-DNA adducts are discussed.

20 For nuclear genomes, cisplatin-DNA adducts are enriched within promoters and

21 Because cisplatin-DNA adducts block RNA polymerase II unless rem

22 and in terms of the selective recognition of cisplatin-DNA adducts by HMG-domain proteins.

23 DNA substrate containing a single 1,2d(GpG) cisplatin-DNA adduct compared with an undamaged DNA subs

24 lity to translocate on duplex DNA containing cisplatin-DNA adducts compared to control, undamaged dup

25 in Csa(-/-) and Csb(-/-) mice fail to remove cisplatin-DNA adducts efficiently in vitro; and unlike X

26 futile cycles of translesion synthesis past cisplatin-DNA adducts followed by removal of the newly s

27 were not associated with a change in either cisplatin-DNA adduct formation or repair over time.

28 , and there was no increase in the extent of cisplatin-DNA adduct formation.

29 n resistance but do not reduce the extent of cisplatin-DNA adduct formation.

30 in-damaged DNA correlated with the extent of cisplatin-DNA adduct formation.

31 hat is bound with Ku at a DNA end containing cisplatin-DNA adducts has a reduced catalytic rate compa

32 The binding of HMG-domain proteins to cisplatin-DNA adducts has been proposed to divert these

33 However, the genomic pattern of cisplatin-DNA adducts has remained unknown owing to the

34 R8278 treatment resulted in fewer unrepaired cisplatin-DNA adducts in genomic DNA and a higher fracti

35 B4 specifically inhibits repair of the major cisplatin-DNA adducts in TGCT cells by using the human T

36 at DNA binding was essentially unaffected by cisplatin-DNA adducts in the presence or absence of DNA-

37 The potential role of HMG-1 in the repair of cisplatin-DNA adducts is discussed.

38 2-d(ApG) intrastrand cross-link, a prevalent cisplatin-DNA adduct, is excised by the excinuclease fro

39 These data suggest that cisplatin-DNA adducts may compete with specific DNA sequ

40 Cisplatin kills cells by forming cisplatin-DNA adducts, most commonly the Pt-d(GpG) diadd

41 f cis-diamminedichloroplatinum(II) (cis-DDP, cisplatin) DNA adducts over >3000 nucleotides was carrie

42 of duplex DNA substrates with site-specific cisplatin-DNA adducts placed in three different orientat

43 In addition, cisplatin-DNA adduct position resulted in differing degr

44 i with a specific DNA strand orientation and cisplatin-DNA adduct position.

45 s without a functional ERCC-1 do not perform cisplatin-DNA adduct repair.

46 Replicative bypass of cisplatin DNA adducts requires the cooperative actions o

47 The crystal structure of the same cisplatin-DNA adduct reveals not only the bent DNA duple

48 least an order of magnitude more tightly to cisplatin-DNA adducts than to unmodified DNA.

49 th hSRY and the hSRY-HMG domain for a single cisplatin-DNA adduct were comparable to those for the pu